Cited by 225Circadian rhythm and melatoninNeuroscience and Neuropharmacology ResearchTryptophan and brain disorders

Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl

Open access
Behan, W M H, McDonald, M, Darlington, L G, Stone, T W·1999·British Journal of Pharmacology

Abstract

There are differences between the excitotoxic actions of quinolinic acid and N‐methyl‐D‐aspartate (NMDA) which suggest that quinolinic acid may act by mechanisms additional to the activation of NMDA receptors. The present study was designed to examine the effect of a potent antioxidant, melatonin, and the potential neuroprotectant, deprenyl, as inhibitors of quinolinic acid‐induced brain damage. Injections were made into the hippocampus of anaesthetized rats, which were allowed to recover before the brains were taken for histology and the counting of surviving neurones. Quinolinic acid (120 nmols) induced damage to the pyramidal cell layer, which was prevented by the co‐administration of melatonin (5 nmols locally plus 2×20 mg kg−1 i.p.). This protective effect was not prevented by the melatonin receptor blocker luzindole. Neuronal damage produced by NMDA (120 nmols) was not prevented by melatonin. Quinolinic acid increased the formation of lipid peroxidation products from hippocampal tissue and this effect was prevented by melatonin. Deprenyl also prevented quinolinic acid‐induced damage at a dose of 50 nmols but not 10 nmols plus 2×1.0 mg kg−1 i.p. The non‐selective monoamine oxidase inhibitor nialamide (10 and 50 nmols plus 2×25 mg kg−1) did not afford protection. The results suggest that quinolinic acid‐induced neuronal damage can be prevented by a receptor‐independent action of melatonin and deprenyl, agents which can act as a potent free radical scavenger and can increase the activity of endogenous antioxidant enzymes respectively. This suggests that free radical formation contributes significantly to quinolinic acid‐induced damage in vivo. British Journal of Pharmacology (1999) 128, 1754–1760; doi:10.1038/sj.bjp.0702940

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0702940

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Behan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W.
Affiliations
  • University of Glasgow (GB)
  • Epsom Hospital (GB)
Corresponding author
Stone, T W
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1999-12
Volume
128
Issue
8
Pages
1754-1760
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2083949851
Cited by
225
References
55
Citations by year
2026: 6 · 2025: 7 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 6 · 2017: 12 · 2016: 7 · 2015: 11 · 2014: 7 · 2013: 5 · 2012: 13
FWCI
3.43
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
quinolinic acid, hippocampal neuronal damage, oxidative stress, melatonin, selegiline, excitotoxicity, NMDA receptor, lipid peroxidation, free radical scavenging, neuroprotection, monoamine oxidase inhibition, nialamide, pyramidal neurons, antioxidant enzymes
MeSH terms
Animals, Antioxidants, Hippocampus, Male, Melatonin, Selegiline, Lipid Peroxidation, Rats, Wistar, Quinolinic Acid, Oxidative Stress, Neuroprotective Agents, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review